About Contact Us Careers

Positive Allosteric Modulators Market Size & Share, by Disease Type (Parkinson disease, Schizophrenia, Alzheimer disease); Drug Type {Galantamine, Benzodiazepines (Diazepam, Clonazepam, Lorazepam), Barbiturates (Methohexital, Phenobarbital, Secobarbital), Amantadine, Donepezil, Levodopa}; End-user (Hospital, Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3979
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Positive Allosteric Modulators Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Allosteric modulators are substances that bind to a receptor to change the receptor's response to stimulus. Positive allosteric modulators function to facilitate agonist-mediated response. The growth of the market can be attributed to the increasing prevalence of mental disorders, such as, dementia, schizophrenia, and others, as positive allosteric modulators are used as a novel treatment approach for the patients. Positive allosteric modulators can be provided to the patients in combination with their currently approved anti-AD drugs, to improve the efficacy of the drugs. The growing cases of Alzheimer’s disease is anticipated to primarily drive the market growth. As per the data by the World Health Organization (WHO), 55 million people live with dementia worldwide, as of 2020, and there are nearly 10 million new cases every year. Out of these 60-70% cases are of Alzheimer’s disease. Moreover, allosteric modulators are also used for medical research and development of new drugs. As per the data by the World Bank, 9.858% of the global gross domestic product (GDP) was spent on healthcare, while research and development expenditure amounted to 2.203% of the GDP in 2018.

Positive-Allosteric-Modulators-Market
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Increasing Prevalence of Severe Mental Disorders
  • Growing Medical Research and Development Activities

Challenges

  • Side Effects of the Drugs

  • Poor Adoption of Advanced Technology in Low-income Regions

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Positive Allosteric Modulators Segmentation

The market is segmented by disease type into Parkinson’s disease, schizophrenia, Alzheimer’s disease, and others out of which, the Alzheimer’s disease segment is anticipated to hold a substantial share in the global positive allosteric modulators market over the forecast period on account of high prevalence of the disorder across the globe. Meanwhile, the Parkinson’s disease segment is also estimated to hold a notable size in the market during the forecast period, owing to the ongoing growth in the cases of the disease. According to the statistics by the Parkinson’s Foundation, more than 10 million people are living with this disorder globally.

Our in-depth analysis of the global positive allosteric modulators market includes the following segments:

     By Disease Type
  • Parkinson’s disease
  • Schizophrenia
  • Alzheimer’s disease
  • Others

          By Drug Type
  • Galantamine
  • Benzodiazepines
    • Diazepam
    • Clonazepam
    • Lorazepam
    • Others
  • Barbiturates
    • Methohexital
    • Phenobarbital
    • Secobarbital
  • Amantadine
  • Donepezil
  • Levodopa
  • Others

          By End User
  • Hospitals
  • Pharmacy
  • Others
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Positive Allosteric Modulators Industry - Regional Synopsis

On the basis of geographical analysis, the global positive allosteric modulators market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is likely to hold largest revenue share by 2037, on account of increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.

The positive allosteric modulators market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the higher health awareness amongst the population, along with easy access of quality healthcare in the developed nations, such as, the United States. Moreover, the higher investment in the R&D activities in the region is further expected to boost the market growth. As per the World Bank data, 2.734% of GDP of North America was spend for R&D activities in 2018.

Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Positive Allosteric Modulators Landscape

    • Acadia Pharmaceuticals Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • Novartis AG
    • Bayer AG
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Siemens Healthcare GmbH
    • Pfizer Inc.

Recent Developments

  • February 16, 2022: Acadia Pharmaceuticals Inc. announced the FDA submission of supplemental New Drug Application (sNDA) for Pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

  • June 11, 2020: Interim HealthCare Inc., launched a free dementia caregiver’s guide for homecare for patients living with dementia or Alzheimer’s disease.

  • Report ID: 3979
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

Positive Allosteric Modulators Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

The increasing prevalence of Parkinson’s disease, schizophrenia, Alzheimer’s disease, and other mental disorder will boost the market growth.

Asia Pacific industry is likely to hold largest revenue share by 2037, on account of increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.

The major players in the market are Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, and Pfizer Inc.

Positive Allosteric Modulators Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos